For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes.

The FDA has accepted for review the resubmitted New Drug Application for reproxalap for the signs and symptoms of dry eye disease.

Frailty and glaucoma may have a proportional relationship, and patients with higher frailty metrics may face significant barriers to regular eye screening and disease management.